Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non–Small-Cell Lung Cancer

Joel W. Neal,Daniel B. Costa,Alona Muzikansky,Joseph B. Shrager,Michael Lanuti,James Huang,Kavitha J. Ramachandran,Deepa Rangachari,Mark S. Huberman,Zofia Piotrowska,Mark G. Kris,Christopher G. Azzoli,Lecia V. Sequist,Jamie E. Chaft

Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non–Small-Cell Lung Cancer

2021

Joel W. Neal
Daniel B. Costa
Alona Muzikansky
Joseph B. Shrager
Michael Lanuti
James Huang
Kavitha J. Ramachandran
Deepa Rangachari
Mark S. Huberman
Zofia Piotrowska
Mark G. Kris
Christopher G. Azzoli
Lecia V. Sequist
Jamie E. Chaft

PURPOSEFor patients with surgically resected disease, multiple studies suggest a benefit of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in delaying cancer recurrence. ...

Keywords:

Phases of clinical research
Adjuvant
Tyrosine kinase
Disease
Medicine
Cancer research
Afatinib
Epidermal growth factor receptor
Mutant
Lung cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations